Evolocumab
Top View
- Evolocumab - Drugbank
- Repatha, INN-Evolocumab
- Evolocumab (Repatha) for Cardiovascular Event Prevention – Add on Therapy
- Lipotropics, Other
- CLINICAL REVIEW(S) Clinical Review Ovidiu A
- Introduction Bile Acid Sequestrants
- New Approaches to Lipid Modification
- Pathway for Prescribing PCSK9 Inhibitors; Alirocumab (Praluent, Sanofi) ▼And Evolocumab (Repatha, Amgen) ▼
- Genetics of Dyslipidemia
- REPATHA (Evolocumab)
- Policy Recommendations
- REPATHA (Evolocumab) Injection, for Subcutaneous Use (On-Body Infusor with Prefilled Cartridge) (3) Initial U.S
- Bempedoic Acid 180Mg Film-Coated Tablets (Nilemdo®) Daiichi Sankyo UK Ltd
- PCSK9 Inhibition: the Way Forward in the Treatment of Dyslipidemia Robert M
- Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
- Repatha, INN-Evolocumab
- Australian Public Assessment Report for Evolocumab (Rch)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019